At the time of writing, Cogent Biosciences Inc [COGT] stock is trading at $39.25, up 3.86%. An important factor to consider is whether the stock is rising or falling in short-term value. The COGT shares have gain 10.35% over the last week, with a monthly amount drifted -2.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on November 10, 2025, when Wedbush upgraded its rating to a Outperform but kept the price target unchanged to $38 for it. Previously, Stifel upgraded its rating to Buy on November 10, 2025, and kept the price target unchanged to $40. On October 16, 2025, Stifel initiated with a Hold rating and assigned a price target of $16 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $30 on September 03, 2025. Scotiabank initiated its recommendation with a Sector Outperform and recommended $17 as its price target on March 07, 2025. Needham downgraded its rating to Hold for this stock on December 11, 2024. In a note dated February 26, 2024, Robert W. Baird downgraded an Neutral rating on this stock and revised its target price from $14 to $8.
For the past year, the stock price of Cogent Biosciences Inc fluctuated between $3.72 and $43.73. Currently, Wall Street analysts expect the stock to reach $45.43 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $39.25 at the most recent close of the market. An investor can expect a potential return of 15.75% based on the average COGT price forecast.
Analyzing the COGT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is -1.26 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Cogent Biosciences Inc [NASDAQ:COGT] has a current ratio of 6.38. On the other hand, the Quick Ratio is 6.38, and the Cash Ratio is 2.01.
Transactions by insiders
Recent insider trading involved Kearns Evan, Chief Legal Officer, that happened on Dec 26 ’25 when 65000.0 shares were sold. Chief Financial Officer, Green John L. completed a deal on Dec 26 ’25 to sell 77000.0 shares. Meanwhile, Chief Medical Officer Sachs Jessica sold 82642.0 shares on Dec 26 ’25.
